SHL Telemedicine Ltd. (SHLT)
- Business Wire
SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones
TEL AVIV, Israel & ZURICH & NEW YORK, April 17, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation.
- Business Wire
Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care
TEL AVIV & ZURICH & NEW YORK, April 11, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial. The randomized clinical trial showcased, among other things, how SHL’s SmartHeart® 12-lead ECG technology can significantly reduce hospital readmissions and ED visits for post-MI (heart attack) pati
- Business Wire
SHL Telemedicine’s SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment
TEL AVIV, Israel & ZURICH & NEW YORK, April 08, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions is pleased to share that in a remarkable display of innovation and operational excellence, the Company’s SmartHeart®, portable 12-lead ECG technology showcased its unparalleled capabilities and successfully participated in Project Convergence – Capstone 4 (PC-C4), the largest, two-phase, "in-
